Browse studies

Find your next paid study

5 recruiting studies matching your filters

A Phase II Study of the Non-Covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab in Patients With Marginal Zone Lymphoma

This phase II trial tests the effect of nemtabrutinib in combination with rituximab in treating patients with marginal zone lymphoma. Nemtabrutinib, a non-cova…

Conjunctival Mucosa-Associated Lymphoid Tissue LymphomaGastric Mucosa-Associated Lymphoid Tissue LymphomaMarginal Zone Lymphoma+4 more

Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07583810

Phase 2

Phase II Trial of Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma (EMZL) (ML44933)

The purpose of this study is to test a new medication called Mosunetuzumab to see if it can help people with Extranodal Marginal Zone Lymphoma (EMZL). This stu…

Extranodal Marginal Zone Lymphoma

Estimated

~$10 – $7,500

Izidore Lossos, MDNCT06569680

Phase 2

Phase 2 Trial of Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)

The purpose of this study is to assess if an investigational treatment of Epcoritamab will be beneficial for patients with Marginal Zone Lymphoma (MZL).

Marginal Zone LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueSplenic Marginal Zone Lymphoma+1 more

Estimated

~$10 – $7,500

Izidore Lossos, MDNCT06796998

Phase 1

Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

This study will combine both T cells and antibodies in order to create a more effective treatment. The treatment tested in this study uses modified T-cells cal…

Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more

Estimated

~$10 – $6,250

UNC Lineberger Comprehensive Cancer CenterNCT04223765

Phase 1

Feasibility of Treating Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma With Zanubrutinib in Combination With the BCL2 Inhibitor, Sonrotoclax, Focusing on Access for Underrepresented Ethnic/Racial Minorities

This phase I trial tests zanubrutinib in combination with sonrotoclax for treating underrepresented ethnic and racial minorities with B-cell non-Hodgkin lympho…

Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more

Estimated